# Generalized Anxiety Disorder Adjunct Study

> **NCT00534599** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 409 (actual)

## Conditions studied

- Anxiety
- Anxiety Disorders
- Anxiety Neuroses
- Anxiety States

## Interventions

- **DRUG:** Placebo
- **DRUG:** quetiapine fumarate XR

## Key facts

- **NCT ID:** NCT00534599
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2011-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534599, "Generalized Anxiety Disorder Adjunct Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00534599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*